Incorporating economies of scale in the cost estimation in economic evaluation of PCV and HPV vaccination programmes in the Philippines: a game changer?

Table 6 Incremental cost-effectiveness ratio of HPV vaccination plus cervical cancer screening compared to cervical cancer screening alone: Incremental cost-effectiveness ratio of HPV vaccination and cervical cancer screening without taking into account economies of scale

ICER (USD/QALY)	Percent coverage of screening (not taking into account EoS approach)
Percent coverage of HPV vaccine (not taking into account EoS approach)		10	20	30	40	50	60	70	80	90	100
	10	− 30^a	120^b	270^b	440^b	600^b	770^b	940^b	1120^b	1300^b	1480^b
	20	− 30^a	120^b	270^b	440^b	600^b	770^b	940^b	1120^b	1300^b	1480^b
	30	− 30^a	120^b	270^b	440^b	600^b	770^b	940^b	1120^b	1300^b	1480^b
	40	− 30^a	120^b	270^b	440^b	600^b	770^b	940^b	1120^b	1300^b	1480^b
	50	− 30^a	120^b	270^b	440^b	600^b	770^b	940^b	1120^b	1300^b	1480^b
	60	− 30^a	120^b	270^b	440^b	600^b	770^b	940^b	1120^b	1300^b	1480^b
	70	− 30^a	120^b	270^b	440^b	600^b	770^b	940^b	1120^b	1300^b	1480^b
	80	− 30^a	120^b	270^b	440^b	600^b	770^b	940^b	1120^b	1300^b	1480^b
	90	− 30^a	120^b	270^b	440^b	600^b	770^b	940^b	1120^b	1300^b	1480^b
	100	− 30^a	120^b	270^b	440^b	600^b	770^b	940^b	1120^b	1300^b	1480^b

ICER incremental cost-effectiveness ratio, EoS economies of scale, HPV human papillomavirus vaccine
^aCost-effective
^bCost-ineffective

ISSN: 1478-7547